UPDATE: Actavis Launches Generic Version of Intuniv

Actavis plc (NYSE: ACT) today announcedthat it has launched a generic version of Intuniv(R) (guanfacinehydrochloride), as part of a settlement agreement with Shire plc. Actavishas begun shipping the product and, under applicable Hatch Waxman rules, isentitled to 180 days of marketing exclusivity. Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO Intuniv(R) is a prescription medicine used to treat Attention DeficitHyperactivity Disorder in patients ages 6 to 17. For the 12-month periodending June 30, 2014, Intuniv(R) had U.S. sales of approximately $668million, according to IMS Health data. About Actavis Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a uniquespecialty pharmaceutical company focused on developing, manufacturing andcommercializing high quality affordable generic and innovative brandedpharmaceutical products for patients around the world. Actavis markets a broad portfolio of branded and generic pharmaceuticals anddevelops innovative medicines for patients suffering from diseasesprincipally in the central nervous system, gastroenterology, women's health,urology, cardiovascular, respiratory and anti-infective therapeuticcategories. The company is an industry leader in product research anddevelopment, with one of the broadest brand development pipelines in thepharmaceutical industry, and a leading position in the submission of genericproduct applications. Actavis has commercial operations in more than 60countries and operates more than 30 manufacturing and distributionfacilities around the world.